SequelSEC

Kraig Biocraft Laboratories, Inc. KBLB

Plastic Material, Synth Resin/Rubber, Cellulos (No Glass) · CIK 0001413119 · Fiscal year ends 1231

Revenue
$0
Fiscal year ended 2019-09-30
Operating income
-$2.24M
Fiscal year ended 2019-09-30
Free cash flow
-$908.19K
Fiscal year ended 2019-09-30

Kraig Biocraft Laboratories, Inc. (KBLB) reported revenue of $0 and net income of -$2.50M for the fiscal year ended 2019-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Kraig Biocraft Laboratories, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Plastic Material, Synth Resin/Rubber, Cellulos (No Glass).

Income

Kraig Biocraft Laboratories, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-09-30
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$2.24M
Net income-$2.50M
Research & development$144.06K
Weighted-average diluted sharesUnavailable
Pretax income-$2.50M
Income tax expense$0
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$1.18M
Selling & marketingUnavailable

Balance

Kraig Biocraft Laboratories, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-09-30
Cash & equivalents$283.15K
Total assets$898.61K
Current assets$295.82K
Total liabilities$5.50M
Current liabilities$4.90M
Total equity incl. NCI-$4.61M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

Kraig Biocraft Laboratories, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-09-30
Operating cash flow-$835.22K
Capital expenditures$72.97K
Investing cash flow-$72.97K
Financing cash flow$1.17M
Net change in cash$260.81K
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$29.27K

Derived

Kraig Biocraft Laboratories, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-09-30
Free cash flow-$908.19K
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio0.06x
Revenue YoY growth-100.0%
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open KBLB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.